Combination of Ruthenium Dendrimers and Acoustically Propelled Gold Nanowires as a Platform for Active Intracellular Drug Delivery Towards Breast Cancer Therapy

In this work, a new class of fluorescently labeled metallodendrimers based on ruthenium and possessing anticancer activity (FITC-CRD13) is combined with graphene oxide modified gold nanowires (GOAuNWs). The resulting complexes were tested as active intracellular transporters being propelled by ultrasound field (US) and using breast cancer cells as a model. Energy dispersive X-ray spectroscopy analysis confirmed the successful modification of GO-AuNWs by dendrimers as shown by the uniform presence of ruthenium over the nanomotor structure corresponding to the ruthenium groups of FITC-CRD13. The binding of dendrimers to the surface of GO-AuNWs was accompanied by quenching their fluorescence signal. Upon the application of an ultrasound field (5 min, 2 V, 2.66 MHz), the complexes were propelled towards MCF7 breast cancer cells, detaching from the GO-nanomotor surface and thus recovering the dendrimer fluorescence signal. Fluorescence signal from US-treated samples was ~1.8 fold higher compared to passive controls. The results obtained in this work suggest that US-propelled AuNWs lead to faster cell internalization, hence accelerating the delivery of the carbosilane ruthenium dendrimers (CRD) payload inside MCF7 cells.


European Cooperation in Science and Technology (COST) logo
EU flag logo

Funded by the Horizon 2020 Framework Programme
of the European Union